MedPath

Beta Testing of a Smartphone App for HIV Prevention in Malaysian MSM

Not Applicable
Completed
Conditions
HIV Prevention Program
Interventions
Other: App usage assessments and analytics
Registration Number
NCT05052411
Lead Sponsor
University of Connecticut
Brief Summary

This project will involve beta testing of the JomPrEP app to assess its usability and acceptability among Malaysian MSM.

Detailed Description

Given the evolving HIV epidemic among MSM and their challenges with accessing prevention services, we previously proposed to adapt, expand, and refine an existing app (namely the HealthMindr app) to deliver an integrated HIV prevention intervention that will promote HIV testing and linkage to PrEP and that incorporates screening and support for P/SUD for Malaysian MSM. We now plan to conduct expanded beta testing of the newly designed JomPrEP app to assess its usability and acceptability among Malaysian MSM.

Following wireframing and usability testing, Keymind (an experienced mobile app development company that has significant experience in building HIPAA-compliant apps, including HealthMindr) will apply a user interface (UI) design (i.e., colors/branding) to the interactive prototype, followed by the final development of the app (beta version). The objective of this study is to beta test this app to identify potential bugs and to ensure its usability in a real-world setting.

As part of the expanded beta testing, we will also evaluate the design, functionality, and usability of the JomPrEP app. This step is a critical stage of app development and will increase the ability of our research team to develop an acceptable and effective app.

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
50
Inclusion Criteria
  • HIV-negative MSM
  • Age more than or equal to 18
  • Cis-gender men
  • Condomless sex in the last 30 days
  • Own a smartphone
Exclusion Criteria
  • Unable to provide informed consent
  • Unable to read and understand English or Bahasa Malaysia

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Expanded beta testing of the JomPrEP appApp usage assessments and analyticsApp usage assessments and analytics over a 1-month period.
Primary Outcome Measures
NameTimeMethod
Usability of the JomPrEP app through the System Usability Scale1 month

The Systems Usability Scale (SUS) will be used to assess the subjective usability of the app.

Usability of the JomPrEP app through app analytics1 month

The investigators will collect app analytics, such as the duration of use of app components to assess usability.

Usability of the JomPrEP app through interviews1 month

Participants will be asked to provide qualitative feedback on functionality, performance, and errors encountered, motivation to use the app, overall experiences using the app, feedback for further refinement, and subjective impact of the app on HIV prevention outcomes.

Acceptability of the JomPrEP app through the System Usability Scale1 month

Point estimates for mean acceptability ≥50 for the System Usability Scale will be considered the minimum criteria for acceptability. The higher the score, the better the outcome. Minimum score for the scale is 0, maximum score is 100.

Acceptability of the JomPrEP app through calculated proportions1 month

Proportion of participants accessing the app \>0.60 will be considered the minimum criteria for acceptability.

Secondary Outcome Measures
NameTimeMethod
Feasibility of the JomPrEP app through the System Usability Scale1 month

Point estimates for mean acceptability ≥50 for the System Usability Scale will be considered the minimum criteria for feasibility. The higher the score, the better the outcome. Minimum score for the scale is 0, highest score is 100.

Feasibility of the JomPrEP app through calculated proportions1 month

Proportion accessing the app \>0.60 will be considered the minimum criteria for feasibility.

Trial Locations

Locations (1)

University of Malaya

🇲🇾

Kuala Lumpur, Malaysia

© Copyright 2025. All Rights Reserved by MedPath